Singapore, Jan. 17 -- Japan headquartered Eisai Co., Ltd. has announced that it has launched the in-house developed anticancer agent Halaven(R) (generic name: eribulin mesylate) in China.

Halaven is a halichondrin class microtubule dynamics inhibitor with a distinct binding profile. In addition to its mechanism of action of inhibiting the growth of microtubule dynamics, non-clinical studies showed Halaven's unique actions on the tumor microenvironment such as increasing vascular perfusion and permeability in tumor cores, promotion of the epithelial state and decrease in the capacity of breast cancer cells to migrate.

In a Phase III clinical study (EMBRACE) of Halaven versus treatment of physician's choice (TPC) in 762 patients with adva...